Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30.
As of today (2026-07-25), Omnicell's 14-Day RSI is 42.23.
The industry rank for Omnicell's 14-Day RSI or its related term are showing as below:
FRA:OC9's 14-Day RSI is ranked better than 81.27% of 694
companies
in the Healthcare Providers & Services industry
Industry Median: 47.15
vs FRA:OC9: 42.23
Omnicell (FRA:OC9) 14-Day RSI Explanation
The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.
Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.
RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections.
Omnicell 14-Day RSI Related Terms
FRA:OC9 vs TDOC, SDGR, OMDA: 14-Day RSI Comparison
For the Health Information Services subindustry, Omnicell's 14-Day RSI, along with its competitors' market caps and 14-Day RSI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Omnicell 14-Day RSI vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Omnicell's 14-Day RSI distribution charts can be found below:
* The bar in red indicates where Omnicell's 14-Day RSI falls into.
* Note that the formula uses a positive value for the average loss.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Omnicell (FRA:OC9) has a 14-Day RSI of 42.23 as of Jul. 25, 2026. Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. View historical data on Omnicell and its competitors. According to the industry distribution chart, Omnicell ranks #130 out of 694 companies in the Healthcare Providers & Services industry, placing it in the top 18.7%.
Is Omnicell's 14-Day RSI too high?
Omnicell's current 14-Day RSI is 42.23. The Healthcare Providers & Services industry median 14-Day RSI is 47.15. Omnicell's value of 42.23 is 10.4% below this industry median. Based on the distribution chart, Omnicell ranks #130 out of 694 companies in the Healthcare Providers & Services industry, which is in the top quartile — a strong position relative to peers. Overall, Omnicell has a GF Score™ of 74/100, reflecting its overall financial health beyond just this single metric.
How does Omnicell's 14-Day RSI compare to TDOC and SDGR?
According to the Healthcare Providers & Services industry distribution chart, Omnicell ranks #130 out of 694 companies for 14-Day RSI. This places Omnicell in the top 19% of its industry — outperforming the majority of peers. The industry median 14-Day RSI is 47.15. Omnicell's value of 42.23 is 10.4% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 14-Day RSI for a Healthcare Providers & Services company?
The median 14-Day RSI among Healthcare Providers & Services companies is 47.15, based on 694 companies in the industry. Companies in the top quartile (top 25%) have a 14-Day RSI significantly above this median, while those in the bottom quartile fall well below. However, 14-Day RSI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Omnicell's current 14-Day RSI of 42.23 is 10.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 14-Day RSI mean?
A high 14-Day RSI can signal that a stock is expensive relative to its fundamentals. Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. View historical data on Omnicell and its competitors. For the Healthcare Providers & Services industry, the median 14-Day RSI is 47.15 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Omnicell's current 14-Day RSI is 42.23. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Omnicell stock overvalued right now?
Omnicell (FRA:OC9) has a current 14-Day RSI of 42.23. The stock's GF Value™ is €33.67, compared to a current price of €35.60 — trading 5.7% above its estimated fair value. The current 14-Day RSI is 42.23 and 10.4% below the Healthcare Providers & Services industry median of 47.15. Omnicell's overall GF Score™ is 74/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 14-Day RSI calculated?
14-Day RSI is calculated from a company's financial statements. For Omnicell (FRA:OC9), the current 14-Day RSI is 42.23 as of Jul. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Omnicell (FRA:OC9) Overvalued in 2026?
Based on GuruFocus' analysis, Omnicell stock appears to be overvalued.
The current stock price of €35.60 is trading 5.7% above its estimated GF Value™ of €33.67.
Key valuation signals for FRA:OC9:
14-Day RSI: 42.23
GF Value™: €33.67 vs. price of €35.60 (5.7% above fair value)
Industry Position: 10.4% below the Healthcare Providers & Services median (#130 of 694)
No single metric tells the full story. See the FRA:OC9 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Omnicell Inc provides automation and business analytics software for healthcare providers. The company is engaged in transforming the pharmacy and nursing care delivery model. The company helps its customers define and deliver cost-effective medication management designed to equip and empower pharmacists and nurses to focus on patient care rather than administrative tasks and drive improved clinical, operational, and financial outcomes across all care settings. The company derives the majority of its revenue from the United States.
74GF Score
Get the complete analysis for FRA:OC9
14-Day RSI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:OC9 has been successfully added to your 
